ArriVent Biopharma
"ArriVent is dedicated to accelerating the global development of innovative biopharmaceutical products."
"With a deep, global network of biotechs and big pharma, ArriVent has access to unique and best-in-class drug candidates at various development stages, including those coming from China and other emerging biotech hubs."
"Through strategic collaborations with innovative biopharma companies, ArriVent aims to globalize medicines for patients with a broad range of diseases, with an initial focus in oncology."
Latest ArriVent Biopharma News & Features
25 January 2024
23 January 2024
24 December 2021
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze